https://www.selleckchem.com/pr....oducts/CP-690550.htm
Using the restricted mean survival time as a summary measure of the survival curve will enhance better treatment decision making in adopting a biosimilar product over the reference product. © The Author(s) 2019. Published by Oxford University Press.Background The 18-year-old age limit for inclusion in clinical trials constitutes a hurdle for adolescents and young adults (AYAs) with cancer. We analyzed the impact of this age barrier on the access of AYAs to cancer trials and novel therapies. Methods ClinicalTrials.gov was searched to i
Like
Comment
Share
